Detalhe da pesquisa
1.
Occupancy maps of 208 chromatin-associated proteins in one human cell type.
Nature
; 583(7818): 720-728, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728244
2.
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Cancer
; 130(4): 541-552, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843249
3.
Using Administrative Data to Examine Telemedicine Usage Among Medicaid Beneficiaries During the Coronavirus Disease 2019 Pandemic.
Med Care
; 60(7): 488-495, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679172
4.
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Br J Cancer
; 125(4): 510-519, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34040175
5.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer
; 125(12): 1666-1676, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34663950
6.
Trends in Health Care Utilization and Expenditures in the United States Across 5 Decades: 1977-2017.
Med Care
; 59(8): 704-710, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33935253
7.
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol
; 163(2): 246-253, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620496
8.
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
Int J Gynecol Cancer
; 30(11): 1824-1828, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32878963
9.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(3): 383-393, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745090
10.
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Br J Cancer
; 120(4): 379-386, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679780
11.
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Br J Cancer
; 118(11): 1425-1433, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765150
12.
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Br J Cancer
; 117(7): 938-946, 2017 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950288
13.
Malignant bowel obstruction in advanced ovarian cancer.
Future Oncol
; 13(6): 513-521, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28095701
14.
Selumetinib in the treatment of non-small-cell lung cancer.
Future Oncol
; 12(22): 2545-2560, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27467210
15.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
J Clin Invest
; 134(2)2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934611
16.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nat Med
; 30(3): 716-729, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38351187
17.
Biomarkers of cell death applicable to early clinical trials.
Exp Cell Res
; 318(11): 1252-9, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22483936
18.
The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
Health Aff (Millwood)
; 42(5): 632-641, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37126754
19.
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Ther Adv Hematol
; 14: 20406207231173489, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273420
20.
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Cancers (Basel)
; 15(16)2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627223